Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases
- PMID: 35229346
- PMCID: PMC9111130
- DOI: 10.1111/1346-8138.16326
Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases
Abstract
Immunoglobulin (Ig)A vasculitis/nephropathy is a systemic immune complex-mediated vasculitis. Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination is widely recommended in individuals without specific allergy to the vaccine components, it is arguable whether vaccination is advisable for patients with IgA vasculitis or for predisposed individuals. We and others have presented cases of IgA vasculitis occurring after SARS-CoV-2 vaccination. In total, these 19 cases, including ours, involved predominantly female patients, and half of them were suffering from de novo vasculitis onset. The most frequent manifestation was gross hematuria (89.5%) while skin lesions were relatively infrequent, occurring in only five cases (26.3%), of which three (15.8%) were confirmed to be IgA vasculitis. Taken together, these cases suggest that SARS-CoV-2 vaccination might be a trigger for development/deterioration of IgA vasculitis/nephropathy.
Keywords: de novo onset; deterioration; immunoglobulin A nephropathy; immunoglobulin A vasculitis; severe acute respiratory syndrome coronavirus 2 vaccination.
© 2022 Japanese Dermatological Association.
Conflict of interest statement
None declared.
Figures
References
-
- Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch‐Schönlein purpura,childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798–806 - PubMed
-
- Rasmussen C, Tisseyre M, Garon‐Czmil J, Atzenhoffer M, Guillevin L, Salem JE, et al. Drug‐induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance‐based approach. Autoimmun Rev. 2021;20:102707 - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
